Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on: December 21,2023 10

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on:December 21,2023 10

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on: December 20,2023 16

Immune cell discovery opens door to new powerful cancer therapies

byUniversity College LondonCredit: CC0 Public DomainScientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the k

Updated on:December 20,2023 16

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023 205

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023 205

How a patient partnership is propelling cancer research

by Leah Eisenstadt,Broad Institute of MIT and HarvardCount Me In Director Nikhil Wagle and Strategic Advisor Corrie Painter. Credit: Broad Institute of MIT and HarvardIn the fall of 2018, cancer

Updated on: December 19,2023 12

How a patient partnership is propelling cancer research

by Leah Eisenstadt,Broad Institute of MIT and HarvardCount Me In Director Nikhil Wagle and Strategic Advisor Corrie Painter. Credit: Broad Institute of MIT and HarvardIn the fall of 2018, cancer

Updated on:December 19,2023 12

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023 87

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023 87

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on: October 15,2023 168

AstraZeneca to Discontinue Moxetumomab Pasudotox in US for Hairy Cell Leukemia

January 13, 2023Chris RyanMoxetumomab pasudotox-tdfk will be permanently discontinued in the United States market for the treatment of relapsed/refractory hairy cell leukemia.Hairy Cell Leukemia (Kate

Updated on:October 15,2023 168

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023 25

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023 25

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on: December 22,2023 15

Engineering the immune system to tackle glioblastoma

by Sally Sapega,University of PennsylvaniaCredit: University of PennsylvaniaEach year, roughly 15,000 Americans are diagnosed with Glioblastoma Multiforme (GBM), the most common malignant primar

Updated on:December 22,2023 15

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on: October 15,2023 142

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on:October 15,2023 142

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on: October 24,2023 4

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25, 2015Jason M. BroderickNivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.Padmanee Sharm

Updated on:October 24,2023 4

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on: December 21,2023 10

Pediatric multicenter study shows targeted therapy for high-risk Hodgkin lymphoma reduces relapse

byEmory UniversityHodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0A targeted therapy for children with high-risk Hodgkin l

Updated on:December 21,2023 10

Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local re

Updated on: December 19,2023 10

Breast-conserving therapy may be a treatment option for some patients with multiple breast lesions

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainPatients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local re

Updated on:December 19,2023 10